Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

Cambridge Isotope Labs Announces the First Commercially Available Quantum-Grade Gas, 12C Methane QG-Alpha™ for High-Performance Nitrogen-Vacancy Center Diamonds

TEWKSBURY, Mass., July 8, 2021 /PRNewswire/ -- Cambridge Isotope Laboratories, Inc. (CIL), part of the Otsuka Group and the world's leading producer of stable isotopes and stable isotope-labeled compounds, is proud to launch the first commercially available 12C-enriched methane-grade gas for quan...

2021-07-08 03:24 1344

Otsuka Signs Three-Year Collaboration with Holmusk to Enhance Digital Health and Data Analytics for Global Behavioral Health Programs

PRINCETON, N.J., July 8, 2021 /PRNewswire/ -- Otsuka Pharmaceutical Development & Commercialization, Inc. ("Otsuka"), announces today that it has entered a three-year collaboration with Holmusk Inc. ("Holmusk"), a global data science and digital health company building the world's largest real-wo...

2021-07-08 00:56 2398

Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific

Introducing VITROS® QC Solutions, taking your lab to the next level with Thermo Scientific™ MAS™ Quality Controls RARITAN, N.J., July 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play, in-vitro diagnostics (IVD) companies, today announced its...

2021-07-07 21:00 30633

dMed-Clinipace Announces Completion of US$50 Million Series C+ Financing from New Investors

SHANGHAI and MORRISVILLE, N.C., July 7, 2021 /PRNewswire/ -- dMed-Clinipace, the global full-service Clinical Contract Research Organization (CRO), announced today the recent successful completion of aUS$50 million Series C+ financing with participation from a group of new, leading international ...

2021-07-07 20:00 2732

Biocytogen/Eucure Biopharma's CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA

BOSTON and BEIJING, July 7, 2021 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing antibody drugs with independent intellectual property rights, announced that the U.S. Food and Drug Administration (FDA) has approved two...

2021-07-07 16:41 1830

Elekta optimizes treatment times for cancer patients via proactive service innovation

STOCKHOLM, July 7, 2021 /PRNewswire/ -- For the last several years, Elekta (EKTA-B.ST) has invested substantially in digitized service solutions to keep critical treatment machines up and running at cancer clinics, thereby ensuring that patients receive timely radiotherapy. Among these solutions ...

2021-07-07 14:38 32068

Innophys' MUSCLE SUIT Selling Steadily after Topping 20,000 Units

TOKYO, July 7, 2021 /PRNewswire/ -- Developed and sold by Innophys Co., Ltd., MUSCLE SUIT has been selling steadily even after exceeding 20,000 units in cumulative total (*1) all over the world recently, making it a fast-selling (*2) exoskeleton assist suit in the world. Notes: (*1) Total numbe...

2021-07-07 14:00 2382

CStone announces China NMPA acceptance of IND application for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody-based molecule, marking further expansion of its Pipeline 2.0 strategy

SUZHOU, China, July 7, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational new ...

2021-07-07 08:05 2429

New Cancer Treatment For Australian Dogs With APVMA Approval Of Qbiotics' Stelfonta®

* STELFONTA® (tigilanol tiglate) is now approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumours (MCT). * APVMA approval follows marketing authorisation (registration) and launch of STELFONTA® in the major co...

2021-07-07 06:34 1567

New Cancer Treatment For Australian Dogs With APVMA Approval Of Qbiotics' Stelfonta®

Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

PROVIDENCE, R.I., July 7, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce that Dr.Amy Rosenberg is leaving the FDA's Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and Protein Therapeutics. Dr. Rosenber...

2021-07-07 01:43 1927

Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002

SUZHOU, China, July 6, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announces that NMPA has accepted IND applica...

2021-07-06 21:36 1462

Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis

* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...

2021-07-06 21:06 17791

Bon Natural Life Limited Announces Land Acquisition to Construct Its Third Production Facility

XIAN, China, July 6, 2021 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solutions provider in the natural, health and personal care industries, today announced that they have received the certificate of a land use right for the future si...

2021-07-06 21:00 3673

RamSoft Acquires a Majority Stake in Meddiff to Advance Patient Care Globally

TORONTO, July 6, 2021 /PRNewswire/ -- RamSoft, a leading healthcare IT software and services company, today announced it has taken a majority stake in Meddiff Technologies, an innovative medical imaging solutions company. This acquisition will accelerate RamSoft's product development by combining...

2021-07-06 21:00 1426

Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD

ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...

2021-07-06 18:00 16816

Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market

* Seegene announces partnership with Bio-Rad for the development and commercialization of infectious disease molecular diagnostic products * Diagnostic tests designed for the pandemic and the post-pandemic era with high multiplex technology * A significant step forward for Seegene in expandi...

2021-07-06 18:00 1615

PolyU develops highly sensitive, microscopic optical fibre sensors with pioneering biomedical monitoring capability

HONG KONG, July 6, 2021 /PRNewswire/ -- The Hong Kong Polytechnic University (PolyU) has made a breakthrough development in optical fibre sensors, making the advanced railway safety monitoring technologies available for medical surveillance inside the human body. The research team led by Profess...

2021-07-06 17:06 1328

Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate

* SPECTRA enrolled over 29,000 adult and elderly participants across four continents achieving high ethnic diversity and robust dataset of circulating strains * Release of vaccine efficacy data anticipated in Q3 2021 and will include sequencing data of SARS-CoV-2 variants of concern and varia...

2021-07-06 14:00 2146

Bora Group announce the rebranding of Yuta Health to Bora Health

TAIPEI, July 6, 2021 /PRNewswire/ -- Leading Taiwan-based contract development and manufacturing organization (CDMO) Bora Group today announced a name change for its subsidiary, currently Yuta Health, to Bora Health Inc. as part of an overall plan to integrate its distribution operations and b...

2021-07-06 13:31 2082

Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China

SAN FRANCISCO and SUZHOU, China, July 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...

2021-07-06 08:00 3556

1 ... 369 370 371372373 374 375 ... 577